Transition to dolutegravir among 21 167 individuals experienced in antiretroviral therapy in West Africa showed heterogeneous timelines and patterns. Initially reported sex disparities tended to catch up over time with persisting disparities, according to contributing HIV clinics. Key factors facilitating dolutegravir switch were male sex, age <50 years, viral suppression, and regimens not based on protease inhibitors.
Keywords: HIV; West Africa; dolutegravir; sex disparities; switch.
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.